We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week?
Read MoreHide Full Article
Key Takeaways
Rezolute climbed 38% after interim upLIFT data showed six of eight tumor HI patients met the endpoint.
RZLT said all six responders fully discontinued IV glucose support with no drug-related safety issues.
Rezolute expects to finish enrollment soon and plans to report top-line results in the second half of 2026.
Shares of Rezolute (RZLT - Free Report) rose 38% over the past week, driven by positive interim results from the late-stage upLIFT study evaluating its lead candidate, ersodetug, in patients with tumor hyperinsulinism (HI), a rare disease that causes dangerously low blood sugar levels.
The interim analysis included the first eight patients enrolled in the study, representing 50% of the targeted enrolment. Six of these patients met the responder criterion for the study's primary endpoint, achieving at least a 50% reduction in intravenous glucose requirements during the eight-week treatment period. Notably, all six responders were able to completely discontinue intravenous glucose support after treatment with ersodetug.
Of the remaining two participants, one was recently enrolled and is currently undergoing dosing. The other withdrew study consent and discontinued treatment before completing the pivotal treatment phase due to the progression of advanced metastatic colon cancer and a transition to hospice care. This patient was therefore classified as a non-responder for the study's primary endpoint assessment.
The findings reinforced investor confidence in ersodetug's potential to address a significant unmet need for a condition with limited treatment options. The company also reported that the therapy was generally well tolerated, with no drug-related safety concerns observed to date.
Rezolute expects to complete enrolment in the study soon and expects to provide top-line results in the second half of 2026.
RZLT’s Stock Performance
Year to date, shares of Rezolute have rallied 94% against the industry’s nearly 5% decline.
Image Source: Zacks Investment Research
upLIFT Study Results Revive Hope for Ersodetug
The encouraging tumor HI data come at an important time for Rezolute. In December, the company's phase III sunRIZE study evaluating ersodetug in congenital HI failed to meet its primary endpoint, sending the stock sharply lower and raising uncertainty about the drug's regulatory path in that indication. However, the study did demonstrate evidence of biological activity and improvements in several glucose-control measures, prompting the company to continue discussions with the FDA regarding potential next steps.
Following a Type B meeting held earlier this year, the FDA encouraged Rezolute to submit comprehensive data from the sunRIZE study and its ongoing open-label extension for further review rather than dismissing the program outright. The company expects to provide an update on the program later this year.
The interim upLIFT results provide investors with renewed confidence in ersodetug's broader potential. While the congenital HI program remains under regulatory review, the strong efficacy signal observed in tumor HI offers another path forward for the company's lead asset and helps diversify the clinical and regulatory risk surrounding the program.
RZLT’s Zacks Rank
Rezolute currently carries a Zacks Rank #3 (Hold).
Over the past 60 days, estimates for Immunocore’s 2026 bottom line have improved from a loss per share of 88 cents to earnings of 6 cents. Over the same period, estimates for 2027 EPS have risen from 24 cents to 87 cents. IMCR’s shares have lost 14% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters but missed the mark on one occasion, delivering an average surprise of 46.66%.
Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 EPS have increased from $3.33 to $4.05. Over the same period, EPS estimates for 2027 have risen to $4.27 from $3.66. INDV’s shares are up 2% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 65.44%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week?
Key Takeaways
Shares of Rezolute (RZLT - Free Report) rose 38% over the past week, driven by positive interim results from the late-stage upLIFT study evaluating its lead candidate, ersodetug, in patients with tumor hyperinsulinism (HI), a rare disease that causes dangerously low blood sugar levels.
The interim analysis included the first eight patients enrolled in the study, representing 50% of the targeted enrolment. Six of these patients met the responder criterion for the study's primary endpoint, achieving at least a 50% reduction in intravenous glucose requirements during the eight-week treatment period. Notably, all six responders were able to completely discontinue intravenous glucose support after treatment with ersodetug.
Of the remaining two participants, one was recently enrolled and is currently undergoing dosing. The other withdrew study consent and discontinued treatment before completing the pivotal treatment phase due to the progression of advanced metastatic colon cancer and a transition to hospice care. This patient was therefore classified as a non-responder for the study's primary endpoint assessment.
The findings reinforced investor confidence in ersodetug's potential to address a significant unmet need for a condition with limited treatment options. The company also reported that the therapy was generally well tolerated, with no drug-related safety concerns observed to date.
Rezolute expects to complete enrolment in the study soon and expects to provide top-line results in the second half of 2026.
RZLT’s Stock Performance
Year to date, shares of Rezolute have rallied 94% against the industry’s nearly 5% decline.
Image Source: Zacks Investment Research
upLIFT Study Results Revive Hope for Ersodetug
The encouraging tumor HI data come at an important time for Rezolute. In December, the company's phase III sunRIZE study evaluating ersodetug in congenital HI failed to meet its primary endpoint, sending the stock sharply lower and raising uncertainty about the drug's regulatory path in that indication. However, the study did demonstrate evidence of biological activity and improvements in several glucose-control measures, prompting the company to continue discussions with the FDA regarding potential next steps.
Following a Type B meeting held earlier this year, the FDA encouraged Rezolute to submit comprehensive data from the sunRIZE study and its ongoing open-label extension for further review rather than dismissing the program outright. The company expects to provide an update on the program later this year.
The interim upLIFT results provide investors with renewed confidence in ersodetug's broader potential. While the congenital HI program remains under regulatory review, the strong efficacy signal observed in tumor HI offers another path forward for the company's lead asset and helps diversify the clinical and regulatory risk surrounding the program.
RZLT’s Zacks Rank
Rezolute currently carries a Zacks Rank #3 (Hold).
Rezolute, Inc. Price
Rezolute, Inc. price | Rezolute, Inc. Quote
Key Picks Among Biotech Stocks
Some better-ranked stocks from the sector are Immunocore (IMCR - Free Report) and Indivior Pharmaceuticals (INDV - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Immunocore’s 2026 bottom line have improved from a loss per share of 88 cents to earnings of 6 cents. Over the same period, estimates for 2027 EPS have risen from 24 cents to 87 cents. IMCR’s shares have lost 14% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters but missed the mark on one occasion, delivering an average surprise of 46.66%.
Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 EPS have increased from $3.33 to $4.05. Over the same period, EPS estimates for 2027 have risen to $4.27 from $3.66. INDV’s shares are up 2% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 65.44%.